

Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders.

In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

(Translation)

November 25, 2024

To Shareholders,

Company Name: Renascience Inc.
Representative: Keisuke Furuta, President & CEO
(Code: 4889 TSE Growth)
For inquiries, please contact Administration Dept.

Notice of termination of joint development and option contract with ASKA Pharmaceutical Co., Ltd. regarding PMS/PMDD treatment drug

We terminated our joint development and option agreement with ASKA Pharmaceutical Co., Ltd. (Head office: Minato-ku, Tokyo; President : Sohta Yamaguchi) for the treatment of PMS/PMDD.

With the completion of the "Phase II investigator-initiated clinical trial of pyridoxamine RS8001 for premenstrual syndrome with psychiatric symptoms/premenstrual dysphoric disorder" (disclosed on June 21, 2024), the Japan Agency for Medical Research and Development (AMED)'s Cyclic Clinical Innovation Program (CiCLE), which had been implemented since 2020, has also ended. Therefore, as of December 24, 2019, the joint development and option contract for PMS/PMDD treatment drugs with ASKA Pharmaceutical Co., Ltd. has been terminated.

There is no impact on the business results for the fiscal year ending March 31, 2025.